In response to the high-cost of new hepatitis C drugs, the American Academy of Actuaries suggests policies to improve state Medicaid officials' handling of the approaching wave of specialty drugs, including use of risk-mitigation strategies already used in Medicare Part D for unexpectedly expensive deliveries. Actuaries say they are having trouble setting capitated Medicaid rates because FDA accelerated its reviews of breakthrough drugs, and such drugs tend to be so expensive that the current approach of using historical experience to...